Obinutuzumab for Treatment of Refractory Lupus Nephritis (KIDNEY WEEK 2024) - Sep 23, 2024 - Abstract #TH-PO638; Pres time: Oct 24, 2024; 10:00 AM - 12:00 PM; Location: Exhibit Hall, Convention Center; "Obinutuzumab has shown efficacy in addition to mycophenolate mofetil (MMF) in LN...All patients were on angiotensin convertase inhibitor (ACE-i) or angiotensin receptor blocker (ARB), and 87.5% of patients were on MMF and hydroxychloroquine, 62% were on tacrolimus, and 12.5% on azathioprine. Among this cohort, 75% had been on cyclophosphamide, 50% had been on rituximab, 50% on voclosporin and 37.5% had been on belimumab... Obinutuzumab therapy along with MMF, HCQ and ACE-i was associated with significant improvement in proteinuria, serum albumin and serum C4 levels in patients with refractory LN. Obinutuzumab could be considered as a treatment option for refractory LN."
Glomerulonephritis • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Varicella Zoster
|
|
Tripti Singh, MD, MBBS, FASN; Shelby Gomez, PharmD; Sarah E. Panzer, MD; Sancia K. Ferguson, MD, MPH; Shivani Garg, MD, MS
|